Medicenna Therapeutics Corp., a clinical stage immunotherapy company, developing proprietary superkines and empowered cytokines, updates its IL-2 Superkine program MDNA109, the only IL-2 in development that selectively targets CD122 due to its enhanced affinity.
MDNA109 is an engineered version of IL-2 that binds up to 1,000 times more effectively to IL-2R (CD122), greatly increasing its ability to activate and proliferate the immune cells needed to fight cancer. MDNA109 is an IL-2 Superkine that preferentially drives the expansion and responses of effector T cells and Natural Killer (NK) cells over Treg cells. It is the only IL-2 in development with a distinct mechanism with a high affinity towards CD122 allowing it to effectively combat NK cell anergy (exhaustion) which occurs frequently after cancer immunotherapy.
“We believe that MDNA109 is the best in class IL-2 cytokine in development due to its highly selective CD122 targeting, ease of manufacture, superior safety, efficacy and remarkable versatility due to its synergy with check-point inhibitors and ability to develop novel immunocytokines, armed CAR-T cells or oncolytic viruses,” states Dr. Fahar Merchant, chairman, president and CEO of Medicenna. “Furthermore, recent pre-clinical data shows that fusions of MDNA109 with inactive protein scaffolds are long-acting and provide the convenience of easier dosing for the patient without sacrificing the safety and efficacy of MDNA109. We look forward to presenting our progress and results at upcoming conferences.”
Medicenna has made considerable progress in advancing its lead IL-2 Superkine program, MDNA109 with extended half-life characteristics. Additionally, early data of MDNA109 fusions show that it has the potential to achieve extended half-life comparable to or better than other agents in development with the convenience of subcutaneous administration.